Therapeutic area intelligence for Atherosclerosis with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 2
Catalysts: 0
Companies: 0

Companies

No related entities indexed yet.

Assets

Daiichi →

Rigshospitalet →

Recent signals(2)

ClinicalJuly 26, 2026

Daiichi Sankyo Trials Triple Therapy for Coronary Atherosclerosis Without Events

The trial evaluates a triple therapy of bempedoic acid, ezetimibe, and high-intensity statins on coronary plaque in patients without prior ischemic events.

ClinicalJuly 17, 2026

DETECT Study Aims to Identify Asymptomatic Atherosclerosis Prevalence and Risk Factors

The DETECT study aims to determine the prevalence of silent atherosclerosis in adults and identify risk factors for subclinical atherosclerosis.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.